Novo Nordisk Wegovy Pill Surpasses 3 Million US Prescriptions in 5 Months Since January 5 Launch, 80% to GLP-1-Naive Patients
A June 7 Novo Nordisk announcement, timed to ADA 2026, said the Wegovy pill (oral semaglutide 25 mg) had surpassed 3 million US prescriptions since its January 5 launch, with one prescription filled roughly every five seconds. The first million took 12 weeks (to March 23); the next 2 million came in 10 weeks. More than 80% of new Wegovy pill scripts go to patients new to GLP-1 therapy, suggesting market expansion rather than brand switching, and the first international launches outside the US are set for the second half of 2026.